Share price
4 March 2021 | 09:05am
StockMarketWire.com - Pharmaceutical company Futura Medical said it had entered into a licensing agreement with Pride Century Ventures to allow the latter to exclusively develop and commercialise the company s gel-based erectile dysfunction treatment MED3000, in China and South East Asia.
Under the collaboration, profits from sales of the drug in the region would be split 50-50.
Pride Century Ventures, a special purpose vehicle owned by Co-High Investment Management Limited, will provide funding currently estimated to be up to £4 million for development and regulatory approval of MED3000 in the region.
The company also raised up to £2 million from HT Riverwood Multi-Growth Fund from a debt and warrants offering.
Second Century Ventures Joins the Oxford Future of Real Estate Initiative
News provided by
Share this article
Share this article
CHICAGO, Jan. 12, 2021 /PRNewswire/ Second Century Ventures, the strategic investment arm of the National Association of Realtors
®, has joined the Oxford Saïd Business School s Future of Real Estate Initiative. Second Century Ventures is the most active global fund in real estate and operates the award-winning REACH technology growth program. Through this initiative, SCV will collaborate with FORE s industry partners and academics to address key questions around the future of global real estate.
Through partnerships with several industry leaders, including Arcadis UK, CBRE, EY, and Redevco, the FORE Initiative aims to predict many of the changes and challenges real estate can expect to face over the next decade. In joining the program, SCV looks to provide resources and support to the University of Oxford s Research team s efforts akin to that o